The Wnt-dependent signaling pathways as target in oncology drug discovery

Investigational New Drugs

Volumn 24, Issue 4, 2006, Pages 263-280

  Janssens, Nico ^a   Janicot, Michel ^b   Perera, Tim ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

catenin; Cancer; Curcumin; Drug target; Endostatin; Exisulind; Folic acid; Fzd; Gleevec; GSK3; HDAC inhibitors; LRP5; NSAIDS; Oncology; Retinoids; Review; sFRP1; Signaling pathway; Wnt

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BUTYRIC ACID; CELECOXIB; CGP 049090; CURCUMIN; DICLOFENAC; ENDOSTATIN; FLAVONOID; FOLIC ACID; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMATINIB; INDOMETACIN; LITHIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PKF 115584; PKF 222815; PROTEIN INHIBITOR; RETINOL DERIVATIVE; ROFECOXIB; SULINDAC SULFIDE; SULINDAC SULFONE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; WNT PROTEIN; WNT PROTEIN INHIBITOR;

ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; BIPOLAR DISORDER; CAENORHABDITIS ELEGANS; CANCER; CARCINOGENESIS; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; COLORECTAL CANCER; DROSOPHILA MELANOGASTER; DRUG RESEARCH; DRUG TARGETING; EMBRYO DEVELOPMENT; HUMAN; MAMMAL; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RETINOPATHY; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; XENOPUS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 33646532114     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-5199-4     Document Type: Review

References (201)

1. Du SJ, Purcell SM, Christian JL, McGrew LL, Moon RT: Identification of distinct classes and functional domains of Wnts through expression of wild-type and chimeric proteins in Xenopus embryos. Mol Cell Biol 15:2625-2634, 1995
2. Wodarz A, Nusse R: Mechanisms of Wnt signaling in development. Annual Review of Cell & Developmental Biology 14:59-88, 1998
3. Wong GT, Gavin BJ, McMahon AP: Differential transformation of mammary epithelial cells by Wnt genes. Mol Cell Biol 14:6278-6286, 1994
4. Moon RT, DeMarais A, Olson DJ: Responses to Wnt signals in vertebrate embryos may involve changes in cell adhesion and cell movement. J Cell Sci Suppl 17:183-188, 1993
5. Kuhl M: Non-canonical Wnt signaling in Xenopus: regulation of axis formation and gastrulation. Semin Cell Dev Biol 13:243-249, 2002
6. He X, Saint-Jeannet JP, Wang Y, Nathans J, Dawid I, Varmus H: A member of the Frizzled protein family mediating axis induction by Wnt-5A. Science 275:1652-1654, 1997
7. Vincan E: Frizzled/WNT signalling: the insidious promoter of tumour growth and progression. Front Biosci 9:1023-1034, 2004
8. Kawano Y, Kypta R: Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116:2627-2634, 2003
9. Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC: An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 407:535-538, 2000
10. Tamai K, Semenov M, Kato Y, Spokony R, Liu CM, Katsuyama Y, Hess F, Saint-Jeannet JP, He X: LDL-receptor-related proteins in Wnt signal transduction. Nature 407:530-535, 2000
11. Wehrli M, Dougan ST, Caldwell K, O'Keefe L, Schwartz S, Vaizel-Ohayon D, Schejter E, Tomlinson A, DiNardo S: Arrow encodes an LDL-receptor-related protein essential for Wingless signalling. Nature 407:527-530, 2000
12. Carron C, Pascal A, Djiane A, Boucaut JC, Shi DL, Umbhauer M: Frizzled receptor dimerization is sufficient to activate the Wnt/beta-catenin pathway. J Cell Sci 116:2541-2550, 2003
13. Schweizer L, Varmus H: Wnt/Wingless signaling through beta-catenin requires the function of both LRP/Arrow and frizzled classes of receptors. BMC Cell Biol 4:4, 2003
14. Ding Y, Dale T: Wnt signal transduction: kinase cogs in a nanomachine? Trends Biochem Sci 27:327-329, 2002
15. Staal FJ, Noort MM, Strous GJ, Clevers HC: Wnt signals are transmitted through N-terminally dephosphorylated beta-catenin. EMBO Rep 3:63-68, 2002
16. Clevers H, van de Wetering M: TCF/LEF factor earn their wings. Trends Genet 13:485-489, 1997
17. Hurlstone A, Clevers H: T-cell factors: turn-ons and turn-offs. EMBO J 21:2303-2311, 2002
18. Roose J, Clevers H: TCF transcription factors: molecular switches in carcinogenesis. Biochimica et Biophysica Acta 1424:M23-M37, 1999
19. Van de Wetering M., Cavallo R, Dooijes D, van Beest M, van Es J, Loureiro J, Ypma A, Hursh D, Jones T, Bejsovec A, Peifer M, Mortin M, Clevers H: Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 88:789-799, 1997
20. Hecht A, Vleminckx K, Stemmler MP, van Roy F, Kemler R: The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO J 19:1839-1850, 2000
21. Cavallo RA, Cox RT, Moline MM, Roose J, Polevoy GA, Clevers H, Peifer M, Bejsovec A: Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature 395:604-608, 1998
22. Roose J, Molenaar M, Peterson J, Hurenkamp J, Brantjes H, Moerer P, van de WM, Destree O, Clevers H: The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressers. Nature 395:608-612, 1998
23. Waltzer L, Bienz M: The control of beta-catenin and TCF during embryonic development and cancer. Cancer & Metastasis Reviews 18:231-246, 1999
24. Kuhl M, Sheldahl LC, Park M, Miller JR, Moon RT: The WNT/Ca2+ pathway, a new vertebrate Wnt signaling pathway takes shape. Trends Genet 16:279-283, 2000
25. Slusarski DC, Yang-Snyder J, Busa WB, Moon RT: Modulation of embryonic intracellular Ca2+ signaling by Wnt-5A. Dev Biol 182:114-120, 1997
26. Sheldahl LC, Park M, Malbon CC, Moon RT: Protein kinase C is differentially stimulated by Wnt and Frizzled homologs in a G-protein-dependent manner. Curr Biol 9:695-698, 1999
27. Kuhl M, Sheldahl LC, Malbon CC, Moon RT: Ca(2+)/calmodulin-dependent protein kinase II is stimulated by Wnt and Frizzled homologs and promotes ventral cell fates in Xenopus. J Biol Chem 275:12701-12711, 2000
28. Saneyoshi T, Kume S, Amasaki Y, Mikoshiba K: The Wnt/calcium pathway activates NF-AT and promotes ventral cell fate in Xenopus embryos. Nature 417:295-299, 2002
29. Westfall TA, Brimeyer R, Twedt J, Gladon J, Olberding A, Furutani-Seiki M, Slusarski DC: Wnt-5/pipetail functions in vertebrate axis formation as a negative regulator of Wnt/beta-catenin activity. J Cell Biol 162:889-898, 2003
30. Liu XX, Liu T, Slusarski DC, Yang-Snyder J, Malbon CC, Moon RT, Wang HY: Activation of a Frizzled-2/beta-adrenergic receptor chimera promotes Wnt signaling and differentiation of mouse F9 teratocarcinoma cells via G alpha o and G alpha t. Proceedings of the National Academy of Sciences of the United States of America 96:14383-14388, 1999
31. Torres MA, Yang-Snyder JA, Purcell SM, DeMarais AA, McGrew LL, Moon RT: Activities of the Wnt-1 class of secreted signaling factors are antagonized by the Wnt-5A class and by a dominant negative cadherin in early Xenopus development. J Cell Biol 133:1123-1137, 1996
32. Ishitani T, Kishida S, Hyodo-Miura J, Ueno N, Yasuda J, Waterman M, Shibuya H, Moon RT, Ninomiya-Tsuji J, Matsumoto K: The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. Mol Cell Biol 23:131-139, 2003
33. Kuhl M, Geis K, Sheldahl LC, Pukrop T, Moon RT, Wedlich D: Antagonistic regulation of convergent extension movements in Xenopus by Wnt/beta-catenin and Wnt/Ca2+ signaling. Mech Dev 106:61-76, 2001
34. Mlodzik M: Planar cell polarization: do the same mechanisms regulate Drosophila tissue polarity and vertebrate gastrulation? Trends Genet 18:564-571, 2002
35. Tree DR, Ma D, Axelrod JD: A three-tiered mechanism for regulation of planar cell polarity. Semin Cell Dev Biol 13:217-224, 2002
36. Habas R, Dawid IB, He X: Coactivation of Rac and Rho by Wnt/Frizzled signaling is required for vertebrate gastrulation. Genes Dev 17:295-309, 2003
37. Dabdoub A, Donohue MJ, Brennan A, Wolf V, Montcouquiol M, Sassoon DA, Hseih JC, Rubin JS, Salinas PC, Kelley MW: Wnt signaling mediates reorientation of outer hair cell stereociliary bundles in the mammalian cochlea. Development 130:2375-2384, 2003
38. Djiane A, Riou J, Umbhauer M, Boucaut J, Shi D: Role of frizzled 7 in the regulation of convergent extension movements during gastrulation in Xenopus laevis. Development 127:3091-3100, 2000
39. Tada M, Concha ML, Heisenberg CP: Non-canonical Wnt signailing and regulation of gastrulation movements. Semin Cell Dev Biol 13:251-260, 2002
40. Nusse R, Varmus HE: Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31:99-109, 1982
41. Polakis P: Wnt signaling and cancer. Genes Dev 14:1837-1851, 2000
42. Giles RH, van Es JH, Clevers H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653:1-24, 2003
43. Lustig B, Behrens J: The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 129:199-221, 2003
44. Morin PJ, Weeraratna AT: Wnt signaling in human cancer. Cancer Treat Res 115:169-187, 2003
45. Gunther EJ, Moody SE, Belka GK, Hahn KT, Innocent N, Dugan KD, Cardiff RD, Chodosh LA: Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 17:488-501, 2003
46. Lane TF, Leder P: Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice. Oncogene 15:2133-2144, 1997
47. Huguet EL, McMahon JA, McMahon AP, Bicknell R, Harris AL: Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res 54:2615-2621, 1994
48. Smalley MJ, Dale TC: Wnt signaling and mammary tumorigenesis. J Mammary Gland Biol Neoplasia 6:37-52, 2001
49. Holcombe RF, Marsh JL, Waterman ML, Lin F, Milovanovic T, Truong T: Expression of Wnt ligands and Frizzled receptors in colonie mucosa and in colon carcinoma. Mol Pathol 55:220-226, 2002
50. Howe LR, Brown AM: Wnt signaling and breast cancer. Cancer Biol Ther 3:36-41, 2004
51. Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, Trent JM: Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1:279-288, 2002
52. Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, Mayo MW, Kitajewski J, Wang CY: Wnt-1 Signaling Inhibits Apoptosis by Activating beta-Catenin/T Cell Factor-mediated Transcription. J Cell Biol 152:87-96, 2001
53. You L, He B, Xu Z, Uematsu K, Mazieres J, Mikami I, Reguart N, Moody TW, Kitajewski J, McCormick F, Jablons DM: Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 2004
54. You L, He B, Xu Z, Uematsu K, Mazieres J, Fujii N, Mikami I, Reguart N, McIntosh JK, Kashani-Sabet M, McCormick F, Jablons DM: An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res 64:5385-5389, 2004
55. Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E, Dahl E, Wild P, Blaszyk H, Sauter G, Simon R, Schmitt R, Zaak D, Hofstaedter F, Rosenthal A, Baylin SB, Pilarsky C, Hartmann A: Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 84:465-478, 2004
56. Ko J, Ryu KS, Lee YH, Na DS, Kim YS, Oh YM, Kim IS, Kim JW: Human secreted frizzled-related protein is down-regulated and induces apoptosis in human cervical cancer. Exp Cell Res 280:280-287, 2002
57. Ugolini F, Charafe-Jauffret E, Bardou VJ, Geneix J, Adelaide J, Labat-Moleur F, Penault-Llorca F, Longy M, Jacquemier J, Birnbaum D, Pebusque MJ: WNT pathway and mammary carcinogenesis: Loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene 20:5810-5817, 2001
58. To KF, Chan MW, Leung WK, Yu J, Tong JH, Lee TL, Chan FK, Sung JJ: Alterations of frizzled (FzE3) and secreted frizzled related protein (hsFRP) expression in gastric cancer. Life Sci 70:483-489, 2001
59. Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, Chughtai S, Wallis Y, Matthews GM, Morton DG: The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 64:883-888, 2004
60. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG, Baylin SB: A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31:141-149, 2002
61. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Dong CW, Pretlow TP, Yang B, Akiyama Y, van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG, Baylin SB: Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 36:417-422, 2004
62. Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, Kristiansen G, Hsieh JC, Hofstaedter F, Hartmann A, Knuechel R, Rosenthal A, Pilarsky C: WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201:204-212, 2003
63. Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM: Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 64:4717-4720, 2004
64. Kirikoshi H, Sekihara H, Katoh M: Up-regulation of Frizzled-7 (FZD7) in human gastric cancer. Int J Oncol 19:111-115, 2001
65. Rhee CS, Sen M, Lu D, Wu C, Leoni L, Rubin J, Corr M, Carson DA: Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene 21:6598-6605, 2002
66. Sagara N, Toda G, Hirai M, Terada M, Katoh M: Molecular cloning, differential expression, and chromosomal localization of human frizzled-1, frizzled-2, and frizzled-7. Biochem Biophys Res Comm 252:117-122, 1998
67. Terasaki H, Saitoh T, Shiokawa K, Katoh M: Frizzled-10, up-regulated in primary colorectal cancer, is a positive regulator of the. Int J Mol Med 9:107-112, 2002
68. Hoang BH, Kubo T, Healey JH, Sowers R, Mazza B, Yang R, Huvos AG, Meyers PA, Gorlick R: Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 109:106-111, 2004
69. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votraba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML: LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523, 2001
70. Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, De Vernejoul MC, Bollerslev J, Van Hul W: Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72:763-771, 2003
71. Polakis P: The oncogenic activation of beta-catenin. Curr Opin Genet Dev 9:15-21, 1999
72. Su LK, Vogelstein B, Kinzler KW: Association of the APC tumor suppressor protein with catenins. Science 262:1734-1737, 1993
73. Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek TJ, Perry WL III, Lee JJ, Tilghman SM, Gumbiner BM, Costantini F: The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell 90:181-192, 1997
74. Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R, Kuhl M, Wedlich D, Birchmeier W: Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 280:596-599, 1998
75. Hart MJ, de Los SR, Albert IN, Rubinfeld B, Polakis P: Down-regulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 8:573-581, 1998
76. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A: Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO Journal 17:1371-1384, 1998
77. Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, Bodmer WF: Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci USA 94:10330-10334, 1997
78. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW: Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 58:1130-1134, 1998
79. Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Gonzalez S, Tarafa G, Sidransky D, Meltzer SJ, Baylin SB, Herman JG: Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 60:4366-4371, 2000
80. Mimori-Kiyosue Y, Tsukita S: Where is APC going? J Cell Biol 154:1105-1109, 2001
81. Kaplan KB, Burds AA, Swedlow JR, Bekir SS, Sorger PK, Nathke IS: A role for the Adenomatous Polyposis Coli protein in chromosome segregation. Nat Cell Biol 3:429-432, 2001
82. Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Caspar C, van Es JH, Breukel C, Wiegant J, Giles RH, Clevers H: Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 3:433-438, 2001
83. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Murata M, Shimano T, Yamaoka Y, Nakamura Y: AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24:245-250, 2000
84. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512, 1998
85. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben Ze'ev A: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96:5522-5527, 1999
86. Brown PO, Botstein D: Exploring the new world of the genome with DNA microarrays. Nat Genet 21:33-37, 1999
87. Collins FS, Green ED, Guttmacher AE, Guyer MS: A vision for the future of genomics research. Nature 422:835-847, 2003
88. Luo J, Isaacs WB, Trent JM, Duggan DJ: Looking beyond morphology: cancer gene expression profiling using DNA microarrays. Cancer Invest 21:937-949, 2003
89. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med 10:789-799, 2004
90. Miklos GL, Maleszka R: Microarray reality checks in the context of a complex disease. Nat Biotechnol 22:615-621, 2004
91. Smalley WE, DuBois RN: Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 39:1-20, 1997
92. Thun MJ: Aspirin and gastrointestinal cancer. Adv Exp Med Biol 400A:395-402, 1997
93. Jolly K, Cheng KK, Langman MJ: NSAIDs and gastrointestinal cancer prevention. Drugs 62:945-956, 2002
94. Meyskens FL Jr: Chemoprevention of FAP with sulindac. Curr Oncol Rep 4:463, 2002
95. Mahmoud NN, Boolbol SK, Dannenberg AJ, Mestre JR, Bilinski RT, Martucci C, Newmark HL, Chadburn A, Bertagnolli MM: The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 19:87-91, 1998
96. Dihlmann S, Siermann A, von Knebel DM: The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene 20:645-653, 2001
97. Dihlmann S, Klein S, Doeberitz Mv MK: Reduction of beta-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated beta-catenin. Mol Cancer Ther 2:509-516, 2003
98. Nath N, Kashfi K, Chen J, Rigas B: Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. Proc Natl Acad Sci USA 100:12584-12589, 2003
99. Boon EM, Keller JJ, Wormhoudt TA, Giardiello FM, Offerhaus GJ, van der NR, Pals ST: Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 90:224-229, 2004
100. Naishiro Y, Yamada T, Takaoka AS, Hayashi R, Hasegawa F, Imai K, Hirohashi S: Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of beta-catenin/T-cell factor 4-mediated gene transactivation. Cancer Res 61:2751-2758, 2001
101. Gardner SH, Hawcroft G, Hull MA: Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells. Br J Cancer 91:153-163, 2004
102. He TC, Chan TA, Vogelstein B, Kinzler KW: PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99:335-345, 1999
103. Davies GL: Cyclooxygenase-2 and chemoprevention of breast cancer. J Steroid Biochem Mol Biol 86:495-499, 2003
104. Goluboff ET: Exisulind, a selective apoptotic antineoplastic drug. Expert Opin Investig Drugs 10:1875-1882, 2001
105. Sharpe C, Lawrence N, Martinez AA: Wnt signalling: a theme with nuclear variations. Bioessays 23:311-318, 2001
106. Klingelhofer J, Troyanovsky RB, Laur OY, Troyanovsky S: Exchange of catenins in cadherin-catenin complex. Oncogene 22:1181-1188, 2003
107. Li H, Pamukcu R, Thompson WJ: beta-Catenin signaling: therapeutic strategies in oncology. Cancer Biol Ther 1:621-625, 2002
108. Shah S, Pishvaian MJ, Easwaran V, Brown PH, Byers SW: The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation. J Biol Chem 277:25313-25322, 2002
109. Shah S, Hecht A, Pestell R, Byers SW: Trans-repression of beta-catenin activity by nuclear receptors. J Biol Chem 278:48137-48145, 2003
110. Xiao JH, Ghosn C, Hinchman C, Forbes C, Wang J, Snider N, Cordrey A, Zhao Y, Chandraratna RA: Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway. J Biol Chem 278:29954-29962, 2003
111. Mollersen L, Paulsen JE, Olstorn HB, Knutsen HK, Alexander J: Dietary retinoic acid supplementation stimulates intestinal tumour formation and growth in multiple intestinal neoplasia (Min)/+ mice. Carcinogenesis 25:149-153, 2004
112. Wong NA, Pignatelli M: Beta-catenin - a linchpin in colorectal carcinogenesis? Am J Pathol 160:389-401, 2002
113. Hanai J, Gloy J, Karumanchi SA, Kale S, Tang J, Hu G, Chan B, Ramchandran R, Jha V, Sukhatme VP, Sokol S: Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol 158:529-539, 2002
114. Narayan S: Curcumin, a multi-functional chemopreventive agent, blocks growth of colon cancer cells by targeting beta-catenin-mediated transactivation and cell-cell adhesion pathways. J Mol Histol 35:301-307, 2004
115. Jaiswal AS, Marlow BP, Gupta N, Narayan S: Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 21:8414-8427, 2002
116. Park CH, Hahm ER, Park S, Kim HK, Yang CH: The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling. FEBS Lett 579:2965-2971, 2005
117. Aggarwal BB, Kumar A, Bharti AC: Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23:363-398, 2003
118. Chainani-Wu N: Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 9:161-168, 2003
119. Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E, Dicato M, Diederich M: Chemopreventive and therapeutic effects of curcumin. Cancer Lett 223:181-190, 2005
120. Jaszewski R, Millar B, Hatfield JS, Nogothu K, Finkenauer R, Rishi AK, Naumoff JA, Kucuk O, Axelrod BN, Majumdar AP: Folic acid reduces nuclear translocation of beta-catenin in rectal mucosal crypts of patients with colorectal adenomas. Cancer Lett 206:27-33, 2004
121. Nagothu KK, Rishi AK, Jaszewski R, Kucuk O, Majumdar AP: Folic acid mediated inhibition of serum-induced activation of egfr promoter in colon cancer cells. Am J Physiol Gastrointest Liver Physiol 2004
122. Glass CK, Rosenfeld MG: The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14:121-141, 2000
123. Johnstone RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299, 2002
124. Kramer OH, Gottlicher M, Heinzel T: Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 12:294-300, 2001
125. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M: Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5:455-463, 2004
126. Bienz M: TCF: transcriptional activator or represser? Curr Opin Cell Biol 10:366-372, 1998
127. Chen G, Fernandez J, Mische S, Courey AJ: A functional interaction between the histone deacetylase Rpd3 and the corepressor groucho in Drosophila development. Genes & Development 13:2218-2230, 1999
128. Nusse R: WNT targets. Repression and activation. Trends Genet 15:1-3, 1999
129. Bordonaro M, Mariadason JM, Aslam F, Heerdt BG, Augenlicht LH: Butyrate-induced apoptotic cascade in colonic carcinoma cells: modulation of the beta-catenin-Tcf pathway and concordance with effects of sulindac and trichostatin A but not curcumin. Cell Growth Differ 10:713-720, 1999
130. Ohira T, Gemmill RM, Ferguson K, Kusy S, Roche J, Brambilla E, Zeng C, Baron A, Bemis L, Erickson P, Wilder E, Rustgi A, Kitajewski J, Gabrielson E, Bremnes R, Franklin W, Drabkin HA: WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci USA 100:10429-10434, 2003
131. Waltzer L, Bienz M: Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling. Nature 395:521-525, 1998
132. Martinez A, Castro A, Dorronsoro I, Alonso M: Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 22:373-384, 2002
133. Martinez A, Alonso M, Castro A, Perez C, Moreno FJ: First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 45:1292-1299, 2002
134. Cohen P, Goedert M: GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3:479-487, 2004
135. Meijer L, Flajolet M, Greengard P: Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 25:471-480, 2004
136. Alonso M, Martinez A: GSK-3 inhibitors: discoveries and developments. Curr Med Chem 11:755-763, 2004
137. Klein PS, Melton DA: A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93:8455-8459, 1996
138. Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS: Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 278:33067-33077, 2003
139. Jope RS: Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24:441-443, 2003
140. Blaheta RA, Cinatl J Jr: Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 22:492-511, 2002
141. Tariot PN, Loy R, Ryan JM, Porsteinsson A, Ismail S: Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev 54:1567-1577, 2002
142. Gould TD, Manji HK: The Wnt signaling pathway in bipolar disorder. Neuroscientist 8:497-511, 2002
143. Zhou L, An N, Haydon RC, Zhou Q, Cheng H, Peng Y, Jiang W, Luu HH, Vanichakarn P, Szatkowski JP, Park JY, Breyer B, He TC: Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. Cancer Lett 193:161-170, 2003
144. Ross JA, Kasum CM: Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 22:19-34, 2002
145. Lee JH, Park CH, Jung KC, Rhee HS, Yang CH: Negative regulation of beta-catenin/Tcf signaling by naringenin in AGS gastric cancer cell. Biochem Biophys Res Commun 335:771-776, 2005
146. Park CH, Hahm ER, Lee JH, Jung KC, Yang CH: Inhibition of beta-catenin-mediated transactivation by flavanone in AGS gastric cancer cells. Biochem Biophys Res Commun 331:1222-1228, 2005
147. Park CH, Chang JY, Hahm ER, Park S, Kim HK, Yang CH: Quercetin, a potent inhibitor against beta-catenin/Tcf signaling in SW480 colon cancer cells. Biochem Biophys Res Commun 328:227-234, 2005
148. Park CH, Hahm ER, Lee JH, Jung KC, Lee HS, Yang CH: Ionomycin downregulates {beta}-catenin/Tcf signaling in colon cancer cell line. Carcinogenesis 2005
149. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR III, Nusse R: Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423:448-452, 2003
150. Nusse R, Varmus HE: Wnt genes. Cell 69:1073-1087, 1992
151. Bhanot P, Brink M, Samos CH, Hsieh JC, Wang Y, Macke JP, Andrew D, Nathans J, Nusse R: A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature 382:225-230, 1996
152. Hsieh JC, Rattner A, Smallwood PM, Nathans J: Biochemical characterization of Wnt-frizzled interactions using a soluble, biologically active vertebrate Wnt protein. Proceedings of the National Academy of Sciences of the United States of America 96:3546-3551, 1999
153. Hsieh JC: Specificity of WNT-receptor interactions. Front Biosci 9:1333-1338, 2004
154. George SR, O'Dowd BF, Lee SP: G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov 1:808-820, 2002
155. Pandur P, Kuhl M: An arrow for wingless to take-off. Bioessays 23:207-210, 2001
156. Wharton KA Jr: Runnin' with the Dvl: proteins that associate with Dsh/Dvl and their significance to Wnt signal transduction. Dev Biol 253:1-17, 2003
157. Bhat RV, Budd Haeberlein SL, Avila J: Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 89:1313-1317, 2004
158. Cohen P, Goedert M: GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3:479-487, 2004
159. Gould TD, Gray NA, Manji HK: Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice. Pharmacol Res 48:49-53, 2003
160. Wagman AS, Johnson KW, Bussiere DE: Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des 10:1105-1137, 2004
161. Kim JS, Crooks H, Foxworth A, Waldman T: Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors. Mol Cancer Ther 1:1355-1359, 2002
162. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB: Small Interfering RNAs Directed against beta-Catenin Inhibit the in Vitro and in Vivo Growth of Colon Cancer Cells. Clin Cancer Res 9:1291-1300, 2003
163. Bennett CF, Cowsert LM: Antisense modulation of beta-catenin expression. US Patent No. 6,066,500. 2000
164. Tetsu O, McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426, 1999
165. van de Wetering M., Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der HK, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P, van den BM, Soete G, Pals S, Eilers M, Medema R, Clevers H: The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111:241-250, 2002
166. Rother K, Johne C, Spiesbach K, Haugwitz U, Tschop K, Wasner M, Klein-Hitpass L, Moroy T, Mossner J, Engeland K: Identification of Tcf-4 as a transcriptional target of p53 signalling. Oncogene 23:3376-3384, 2004
167. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW, Shivdasani RA: Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 5:91-102, 2004
168. Blaschuk OW, Byers S, Gour BJ: Compounds and methods for modulating beta-catenin mediated gene expression. US Patent No. 6,303,576. 2001
169. Moll J, Knapp S, Dalvit C, Trosset JY, Sundstrom M, Mantegani S: Interaction inhibitors of TCF-4 with beta-catenin. Pharmacia Italia SPA. US Patent No. EP1406889, 14 April 2004
170. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, Moon RT, Teo JL, Oh SW, Kim HY, Moon SH, Ha JR, Kahn M: A small molecule inhibitor of beta-catenin/cyclic AMP response element-binding protein transcription. Proc Natl Acad Sci USA 101:12682-12687, 2004
171. Kahn M, Eguch M, Moon SH, Chung JU, Jeong KW: Compounds useful for treatment of cancer, compositions containing the same, and methods of their use. Choongwae Pharma Corporation. US Patent No. 6,762,185. 2004
172. Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman RH: Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365:855-859, 1993
173. Eckner R, Ewen ME, Newsome D, Gerdes M, DeCaprio JA, Lawrence JB, Livingston DM: Molecular cloning and functional analysis of the adenoviras E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev 8:869-884, 1994
174. Janknecht R, Hunter T: Versatile molecular glue. Transcriptional control. Curr Biol 6:951-954, 1996
175. Takemaru KI, Moon RT: The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J Cell Biol 149:249-254, 2000
176. Easwaran V, Pishvaian M, Salimuddin, Byers S: Cross-regulation of beta-catenin-LEF/TCF and retinoid signaling pathways. Current Biology 9:1415-1418, 1999
177. Minucci S, Pelicci PG: Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin Cell Dev Biol 10:215-225, 1999
178. Daniels DL, Eklof SK, Weis WI: beta-catenin: molecular plasticity and drug design. Trends Biochem Sci 26:672-678, 2001
179. Omer CA, Miller PJ, Diehl RE, Kral AM: Identification of Tcf4 residues involved in high-affinity beta-catenin binding. Biochem Biophys Res Commun 256:584-590, 1999
180. Graham TA, Weaver C, Mao F, Kimelman D, Xu W: Crystal Structure of a beta-Catenin/Tcf Complex. Cell 103:885-896, 2000
181. Spink KE, Polakis P, Weis WI: Structural basis of the Axin-adenomatous polyposis coli interaction. EMBO J 19:2270-2279, 2000
182. Spink KE, Fridman SG, Weis WI: Molecular mechanisms of beta-catenin recognition by adenomatous polyposis coli revealed by the structure of an APC-beta-catenin complex. EMBO J 20:6203-6212, 2001
183. Graham TA, Ferkey DM, Mao F, Kimelman D, Xu W: Tcf4 can specifically recognize beta-catenin using alternative conformations. Nat Struct Biol 8:1048-1052, 2001
184. Poy F, Lepourcelet M, Shivdasani RA, Eck MJ: Structure of a human Tcf4-beta-catenin complex. Nat Struct Biol 8:1053-1057, 2001
185. Moon RT, Kohn AD, De Ferrari GV, Kaykas A: WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5:691-701, 2004
186. Smalley MJ, Dale TC: Wnt signalling in mammalian development and cancer. Cancer & Metastasis Reviews 18:215-230, 1999
187. Janssens N, Andries L, Janicot M, Perera T, Bakker A: Alteration of frizzled expression in renal cell carcinoma. Tumour Biol 25:161-171, 2004
188. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y, Minamoto T: Deregulated GSK3beta activity in colorectal cancer: Its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 334:1365-1373, 2005
189. Manoukian AS, Woodgett JR: Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv Cancer Res 84:203-229, 2002
190. Miyaoka T, Seno H, Ishino H: Increased expression of Wnt-1 in schizophrenic brains. Schizophrenia Research 38:1-6, 1999
191. Kozlovsky N, Regenold WT, Levine J, Rapoport A, Belmaker RH, Agam G: GSK-3beta in cerebrospinal fluid of schizophrenia patients. J Neural Transm 111:1093-1098, 2004
192. Yang J, Si T, Ling Y, Ruan Y, Han Y, Wang X, Zhang H, Kong Q, Li X, Liu C, Zhang D, Zhou M, Yu Y, Liu S, Shu L, Ma D, Wei J, Zhang D: Association study of the human FZD3 locus with schizophrenia. Biol Psychiatry 54:1298-1301, 2003
193. Sen M, Lauterbach K, El Gabalawy H, Firestein GS, Corr M, Carson DA: Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America 97:2791-2796, 2000
194. Sen M, Chamorro M, Reifert J, Corr M, Carson DA: Blockade of Wnt-5A/frizzled 5 signaling inhibits rheumatoid synoviocyte activation. Arthritis Rheum 44:772-781, 2001
195. Loughlin J, Dowling B, Chapman K, Marcelline L, Mustafa Z, Southam L, Ferreira A, Ciesielski C, Carson DA, Corr M: Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females. Proc Natl Acad Sci USA 101:9757-9762, 2004
196. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP: High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521, 2002
197. Niemann S, Zhao C, Pascu F, Stahl U, Aulepp U, Niswander L, Weber JL, Muller U: Homozygous WNT3 mutation causes tetra-amelia in a large consanguineous family. Am J Hum Genet 74:558-563, 2004
198. Robitaille J, MacDonald ML, Kaykas A, Sheldahl LC, Zeisler J, Dube MP, Zhang LH, Singaraja RR, Guernsey DL, Zheng B, Siebert LF, Hoskin-Mott A, Trese MT, Pimstone SN, Shastry BS, Moon RT, Hayden MR, Goldberg YP, Samuels ME: Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nat Genet Frizzled 2002
199. Toomes C, Bottomley HM, Jackson RM, Towns KV, Scott S, Mackey DA, Craig JE, Jiang L, Yang Z, Trembath R, Woodruff G, Gregory-Evans CY, Gregory-Evans K, Parker MJ, Black GC, Downey LM, Zhang K, Inglehearn CF: Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. Am J Hum Genet 74:721-730, 2004
200. Jordan BK, Shen JH, Olaso R, Ingraham HA, Vilain E: Wnt4 overexpression disrupts normal testicular vasculature and inhibits testosterone synthesis by repressing steroidogenic factor 1/beta-catenin synergy. Proc Natl Acad Sci USA 100:10866-10871, 2003
201. Biason-Lauber A, Konrad D, Navratil F, Schoenle EJ: A WNT4 mutation associated with Mullerian-duct regression and virilization in a 46,XX woman. N Engl J Med 351:792-798, 2004